- Home
- DAWN vs ACDC Comparison
DAWN vs ACDC Comparison
Compare DAWN & ACDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DAWN | ACDC |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 971.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DAWN | ACDC |
|---|---|---|
| Price | $12.02 | $5.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 3 |
| Target Price | ★ $27.56 | $5.83 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 04-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.96 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $131,161,000.00 | ★ $2,190,900,000.00 |
| Revenue This Year | $18.59 | N/A |
| Revenue Next Year | $49.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.64 | $3.08 |
| 52 Week High | $13.20 | $10.70 |
Technical Indicators
Market Signals| Indicator | DAWN | ACDC |
|---|---|---|
| Relative Strength Index (RSI) | 57.55 | 48.89 |
| Support Level | $10.07 | $3.53 |
| Resistance Level | $13.20 | $5.31 |
| Average True Range (ATR) | 0.67 | 0.35 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 92.16 | 20.35 |
Price Performance
Historical ComparisonAbout DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About ACDC ProFrac Holding Corp.
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.